Form 4: Dynavax COO Novack Reports Stock Transactions Amid Sanofi Merger

Dynavax Technologies' President & COO, David F. Novack, reported significant stock acquisitions from accelerated vesting and option exercises, alongside sales, following the company's merger agreement with Sanofi.

Summary

• David F. Novack, President & COO of Dynavax Technologies Corp, reported multiple stock transactions on December 23 and 24, 2025.
• Transactions occurred in connection with an Agreement and Plan of Merger dated December 23, 2025, between Dynavax, Sanofi, a French societe anonyme, and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent.
• The merger agreement led to the acceleration of vesting for certain performance-based restricted stock units (PSUs) and restricted stock units (RSUs).
• Novack acquired 60,625 shares from PSUs, which vested at 125% of the target number due to achievement of rTSR performance, with the merger price of $15.50 per share used for valuation.
• An additional 22,620 RSUs (granted February 15, 2024) and 18,788 RSUs (granted February 13, 2025) also vested.
• On December 24, 2025, Novack exercised stock options to acquire 20,000 shares at $6.805 and 10,000 shares at $10.47.
• Concurrently, 30,000 shares were sold at $15.49, and 48,107 shares were withheld by the Issuer at $15.38 to satisfy tax withholding requirements on vesting.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2024.
• Novack's beneficial ownership after these transactions is 63,344 shares.
• The reported beneficial ownership also includes 1,340 shares purchased through the Issuer's Employee Stock Purchase Plan on August 15, 2025.

Sentiment

Score: 7

Explanation: The filing reflects positive developments for the executive, including accelerated vesting and the realization of value through option exercises and sales, all within the context of a definitive merger agreement at a specified price. The pre-planned nature of sales mitigates negative sentiment, and the 125% PSU vesting indicates strong performance leading up to the merger.

Positives

• Acceleration of vesting for 60,625 PSUs and 41,408 RSUs (22,620 + 18,788) due to the merger agreement, allowing the executive to realize value sooner.
• PSUs vested at 125% of the target number, indicating strong performance relative to an indexed group of companies (rTSR).
• The merger agreement with Sanofi at $15.50 per share provides a clear valuation for the company's stock.

Negatives

• The sale of 30,000 shares by a key executive, even if pre-planned, could be perceived negatively by some investors.
• A significant number of shares (48,107) were withheld for tax purposes, reducing the net shares received by the executive.

Future Outlook

The filing indicates a definitive Agreement and Plan of Merger with Sanofi, suggesting the company's future as an independent entity is limited, with a clear acquisition price of $15.50 per share established for the transaction.

Industry Context

The merger agreement with Sanofi positions Dynavax within a broader trend of consolidation in the biotechnology and pharmaceutical sectors, where larger players acquire specialized companies to expand their pipelines or market share. This transaction provides a clear exit strategy and valuation for Dynavax shareholders.

Corporate Governance

Stakeholder Impact

• Shareholders: The merger agreement provides a clear exit at $15.50 per share, offering a defined return on investment.
• Employees (specifically David F. Novack): Benefits from accelerated vesting of equity awards and the ability to exercise options and sell shares, realizing significant compensation.

Next Steps

• Completion of the merger with Sanofi.
• Further integration activities following the merger.

Key Dates

Recommendation

Given the definitive merger agreement with Sanofi at $15.50 per share, the stock price is likely to trade close to this acquisition price until the transaction closes. For investors, holding the stock until the merger completes would allow them to receive the agreed-upon cash consideration. There is limited upside beyond the merger price, and selling now would forgo the final merger consideration.

Keywords

Dynavax Technologies, DVAX, Sanofi, Merger Agreement, Insider Trading, Form 4, Stock Options, Restricted Stock Units, PSUs, RSUs, 10b5-1 Plan, Executive Compensation, David F. Novack